1[1]Tanaka A,Kawarabayashi T,Nishibori Y,et al.No-reflow phenomenon and lesion mophology in patients with acute myocardial infarction.Circulation,2002,105:2148-2152.
2[2]Jones CJ H,DeFily DV,Pat terson JL,et al.Endot helium-dependent relaxation competes with α1-and α2-adrenergic constriction in the canine epicardial coronary microcirculation.Circulation,1993,87:1264.
3[3]Golino P,Ragni M,Cirillo P,et al.Recombinant human,active site blocked factor Ⅶ reduces infarct size and no-reflow phenomenon in atherosclerotic vascular disease.Circulation,2000,278:1507-1516.
4[4]Baim D.On behalf of the SAFER investigators:transcatheter cardio-vascular therapeutics meeting.Washington DC,2000,October.
5[5]Engler RL,Dahlgren MD,Morris DD,et al.Role of leukocytes in response to acute myocardial ischemia and reflow in dogs.Am J Physiol,1986,251:1131-1132.
6[6]Michaels AD,Appleby M,Otten MH,et al.Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions:results of the randomized,controlled vasodilator prevention on no-rellow (VAPOR) trial.J Invasive Cardiol,2002,14:299-302.
7[7]Desmet WJ,Dens J,Coussement P,et al.Does adenosine prevent myocardial micronecrosis following precutaneous coronary intervention? ADELINE pilot trial.ADEnosine Limit myocardial Necrosis.Heart,2002,88:293-295.
8[8]Genda S,Miura T,Miki T,et al.K (ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia.J Am Coll Cardiol,2002,40:1339-1346.
9[9]Tsubokawa A,Ueda K,Sakamoto H,et al.Effect of intracoronary nicorandil administration on preventing no-reflow and slow flow phenomenon during rotational atherectomy.Circ J,2002,66:1119-1123.
10[10]Kaul S,Ito H.Microvasculature in acute myocardial ischemia:part:Ⅱ evolving concepts in pathophysiology,diagnosis,and treatment.Circulation,2004,109:310-315.
